samedan logo

 
 
spacer
home > pmps > summer 2017 > of paramount importance
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Of Paramount Importance

Parenterals are an important segment within the drug delivery field, assuming approximately 30% of the market share. One factor driving this is the substantial emergence of new therapeutic antibodies and advancements in biotechnology, resulting in many improved medications that have led to enhancements in patient wellbeing and life expectancy (1,2).

The realisation and proliferation of recombinant DNA technology led to the development of protein drugs. In particular, the development of monoclonal antibodies (mAbs) as drugs has increased significantly over the past few years. From 2014 onwards, 64 mAbs have been approved, are pending or are in review in Europe and the US. Additionally, more than 200 are in a clinical study stage. As explained by Dr Steven J Shire, mAbs are very specific, binding to a single antigen target, which may lead to fewer side effects than small molecule drugs (3).

Product Control


Biopharmaceuticals are frequently administered through injection using pre-filled syringes (PFSs); however, proteins are inherently unstable, sensitive to heat and oxidisation and have the propensity to aggregate (4-6). This generates the need to control the stability and quality of the drug product (DP), mitigating possible interactions in a risk-based approach for preventing effects on drug efficacy, pharmacokinetics and clinical consequences affecting patient safety.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.


spacer
William Dierick is Director of Technology Development – Global Pharmaceutical Solutions at Terumo: a global R&D company that offers drug delivery devices and injection technology, cardiology and cardiovascular systems, transfusion, patient monitoring and clinical systems. With 40 years of experience in the medical and pharma sector, he has held various positions in the company, covering quality assurance, production and product development to marketing, corporate planning and business development. William serves as expert of ISO/TC76 and ISO/TC84 and is an active member of MedTech Europe and volunteer at PDA.

Dr Piet Christiaens is Scientific Director at Toxikon Europe where he develops analytical methods and protocols for E&L studies for the medical and pharma industries. He oversees all laboratory operations at the company and is supporting the European business development. Piet received his PhD from the Analytical Chemistry Department of the University of Leuven, Belgium, in 1991. 

Dr Wim Van Rossom graduated with an MSc in organic chemistry in 2006 and received his PhD in 2010 from the Catholic University of Leuven, Belgium. In 2011, he moved to Japan where he spent two years as a Postdoctoral Fellow at the National Institute for Materials Science designing synthetic approaches towards macrocyclic structures. He was selected by the European Commission for a Marie Curie Career Integration Grant in 2013 to continue his research at the University of Southampton, UK, as Research Fellow on the topics of supramolecular anion recognition and transmembrane anion transport. Since 2015, he has been Study Director at Toxikon Europe, focusing on E&L studies in parenteral applications. 
spacer
William Dierick
spacer
spacer
spacer
Dr Piet Christiaens
spacer
spacer
spacer
Dr Wim Van Rossom
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis Analysis evaluated 94 confirmed cases of COVID-19 in trial participants Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; safety and additional efficacy data continue to be collected Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints
More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement